SLC2A2 and diabetic kidney disease: Nonetheless, the novel idea of targeting KPTCs-GLUT2 as a potential therapy for DKD may be very tempting, due to the recent results demonstrating that its nullification in KPTCs/whole-kidney has the potential to protect mice from DKD [37,38].